PSMA617-TCMC TFA
| Code | Size | Price |
|---|
| TAR-T28467-2mg | 2mg | £704.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28467-5mg | 5mg | £1,169.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
PSMA617-TCMC is a derivative of PSMA-617 with structure modification, in which the caroboxy groups in DOTA ring is replaced by TCMC macrocycle. PSMA-617 is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer.
CAS:
T28467
Formula:
C65H86F12N14O21S
Molecular Weight:
1659.52
Purity:
0.98
SMILES:
O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC([C@@H](NC([C@H]1CC[C@H](CNC(NC2=CC=C(CC3N(CC(N)=O)CCN(CC(N)=O)CCN(CC(N)=O)CCN(CC(N)=O)C3)C=C2)=S)CC1)=O)CC4=CC=C5C=CC=CC5=C4)=O)=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
References
1. Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600. eCollection 2017 Nov 28. PubMed PMID: 29262549; PubMed Central PMCID: PMC5732715.
2. von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2017 Dec 16. doi: 10.1007/s00259-017-3895-x. [Epub ahead of print] Review. PubMed PMID: 29247284.
3. Rahbar K, Ahmadzadehfar H, Boegemann M. (177)Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? Eur J Nucl Med Mol Imaging. 2017 Nov 21. doi: 10.1007/s00259-017-3892-0. [Epub ahead of print] PubMed PMID: 29164300.
4. Eppard E, de la Fuente A, Bene?ov? M, Khawar A, Bundschuh RA, G?rtner FC, Kreppel B, Kopka K, Essler M, R?sch F. Clinical Translation and First In-Human Use of [(44)Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017. PubMed PMID: 29158832; PubMed Central PMCID: PMC5695136.